{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T22:37:37Z","timestamp":1781649457515,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,28]]},"DOI":"10.7759\/cureus.86932","type":"journal-article","created":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T23:54:27Z","timestamp":1751154867000},"source":"Crossref","is-referenced-by-count":1,"title":["Benralizumab in Corticosteroid-Refractory Drug Reaction With Eosinophilia and Systemic Symptoms: A Case Report"],"prefix":"10.7759","author":[{"given":"Katelin R","family":"Ross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elijah","family":"Horesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milie M","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2004.06.012","article-title":"Life-threatening acute adverse cutaneous drug reactions","volume":"23","author":"Wolf R","year":"2005","unstructured":"Wolf R, Orion E, Marcos B, Matz H. Life-threatening acute adverse cutaneous drug reactions. Clin Dermatol. 2005, 23:171-81. 10.1016\/j.clindermatol.2004.06.012","journal-title":"Clin Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2022.100673","article-title":"DRESS syndrome: a literature review and treatment algorithm","volume":"16","author":"Calle AM","year":"2023","unstructured":"Calle AM, Aguirre N, Ardila JC, Cardona Villa R. DRESS syndrome: a literature review and treatment algorithm. World Allergy Organ J. 2023, 16:100673. 10.1016\/j.waojou.2022.100673","journal-title":"World Allergy Organ J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40629-022-00224-7","article-title":"Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS)","volume":"32","author":"Gschwend A","year":"2022","unstructured":"Gschwend A, Helbling A, Feldmeyer L, et al.. Treatment with IL5-\/IL-5 receptor antagonists in drug reaction with eosinophilia and systemic symptoms (DRESS). Allergo J Int. 2022, 32:1-8. 10.1007\/s40629-022-00224-7","journal-title":"Allergo J Int"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00049","article-title":"Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma","volume":"5","author":"Roufosse F","year":"2018","unstructured":"Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018, 5:49. 10.3389\/fmed.2018.00049","journal-title":"Front Med (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2023.4450","article-title":"Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus","volume":"160","author":"Br\u00fcggen MC","year":"2024","unstructured":"Br\u00fcggen MC, Walsh S, Ameri MM, et al.. Management of adult patients with drug reaction with eosinophilia and systemic symptoms: a Delphi-based international consensus. JAMA Dermatol. 2024, 160:37-44. 10.1001\/jamadermatol.2023.4450","journal-title":"JAMA Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.100935","article-title":"The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids","volume":"17","author":"Wang S","year":"2024","unstructured":"Wang S, Kang Y, He C, Jin H. The systemic treatments for drug reaction with eosinophilia and systemic symptoms (DRESS) beyond corticosteroids. World Allergy Organ J. 2024, 17:100935. 10.1016\/j.waojou.2024.100935","journal-title":"World Allergy Organ J"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair P","year":"2017","unstructured":"Nair P, Wenzel S, Rabe KF, et al.. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017, 376:2448-58. 10.1056\/NEJMoa1703501","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313318","article-title":"Eosinophil depletion with benralizumab for eosinophilic esophagitis","volume":"390","author":"Rothenberg ME","year":"2024","unstructured":"Rothenberg ME, Dellon ES, Collins MH, et al.. Eosinophil depletion with benralizumab for eosinophilic esophagitis. N Engl J Med. 2024, 390:2252-63. 10.1056\/NEJMoa2313318","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224624","article-title":"Benralizumab for eosinophilic granulomatosis with polyangiitis","volume":"82","author":"Cottu A","year":"2023","unstructured":"Cottu A, Groh M, Desaintjean C, et al.. Benralizumab for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2023, 82:1580-6. 10.1136\/ard-2023-224624","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1014","article-title":"Single-center off-label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy","volume":"6","author":"Veltman Y","year":"2025","unstructured":"Veltman Y, Aalbers AM, Hermans MA, Mutsaers PG. Single-center off-label benralizumab use for refractory hypereosinophilic syndrome demonstrates satisfactory safety and efficacy. EJHaem. 2025, 6:e1014. 10.1002\/jha2.1014","journal-title":"EJHaem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.039","article-title":"Benralizumab for severe DRESS in two COVID-19 patients","volume":"9","author":"Schmid-Grendelmeier P","year":"2021","unstructured":"Schmid-Grendelmeier P, Steiger P, Naegeli MC, Kolm I, Claudia C\u00e9cile Val\u00e9rie L, Maverakis E, Br\u00fcggen MC. Benralizumab for severe DRESS in two COVID-19 patients. J Allergy Clin Immunol Pract. 2021, 9:481-3.e2. 10.1016\/j.jaip.2020.09.039","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.047","article-title":"Benralizumab: a\u00a0potential tailored treatment for life-threatening DRESS in the COVID-19 era","volume":"9","author":"Mesli F","year":"2021","unstructured":"Mesli F, Dumont M, Soria A, et al.. Benralizumab: a\u00a0potential tailored treatment for life-threatening DRESS in the COVID-19 era. J Allergy Clin Immunol Pract. 2021, 9:3529-31.e1. 10.1016\/j.jaip.2021.06.047","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.06.048","article-title":"Reply to \"Benralizumab: a\u00a0potential tailored treatment for life-threatening DRESS in the COVID-19 era\"","volume":"9","author":"Lang CC","year":"2021","unstructured":"Lang CC, Schmid-Grendelmeier P, Maverakis E, Br\u00fcggen MC. Reply to \"Benralizumab: a\u00a0potential tailored treatment for life-threatening DRESS in the COVID-19 era\". J Allergy Clin Immunol Pract. 2021, 9:3531-2. 10.1016\/j.jaip.2021.06.048","journal-title":"J Allergy Clin Immunol Pract"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159\/000525752","article-title":"Severe toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms overlap syndrome treated with benralizumab: a case report","volume":"14","author":"Zeller FK","year":"2022","unstructured":"Zeller FK, Bader PR, N\u00e4geli MC, Buehler PK, Schuepbach RA. Severe toxic epidermal necrolysis and drug reaction with eosinophilia and systemic symptoms overlap syndrome treated with benralizumab: a case report. Case Rep Dermatol. 2022, 14:203-9. 10.1159\/000525752","journal-title":"Case Rep Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226642","article-title":"Off-label benralizumab in severe non-necrotizing eosinophilic vasculitis following critical COVID-19 disease and in DRESS","volume":"11","author":"Pintea I","year":"2022","unstructured":"Pintea I, Muntean IA, Dobrican CT, Miron N, Deleanu D. Off-label benralizumab in severe non-necrotizing eosinophilic vasculitis following critical COVID-19 disease and in DRESS. J Clin Med. 2022, 11:6642. 10.3390\/jcm11226642","journal-title":"J Clin Med"},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2024.08.509","article-title":"A case of recalcitrant dress syndrome responsive to combination therapy with benralizumab and upadacitinib","volume":"133","author":"Zhang K","year":"2024","unstructured":"Zhang K, Wangberg H. A case of recalcitrant dress syndrome responsive to combination therapy with benralizumab and upadacitinib. Ann Allergy Asthma Immunol . 2024, 133:S119.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab","volume":"43","author":"Jackson DJ","year":"2020","unstructured":"Jackson DJ, Korn S, Mathur SK, Barker P, Meka VG, Martin UJ, Zangrilli JG. Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab. Drug Saf. 2020, 43:409-25. 10.1007\/s40264-020-00926-3","journal-title":"Drug Saf"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.07.058","article-title":"Integrated safety and efficacy among patients receiving benralizumab for up to 5 years","volume":"9","author":"Korn S","year":"2021","unstructured":"Korn S, Bourdin A, Chupp G, Cosio BG, Arbetter D, Shah M, Gil EG. Integrated safety and efficacy among patients receiving benralizumab for up to 5 years. J Allergy Clin Immunol Pract. 2021, 9:4381-92.e4. 10.1016\/j.jaip.2021.07.058","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/373992-benralizumab-in-corticosteroid-refractory-drug-reaction-with-eosinophilia-and-systemic-symptoms-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T23:54:27Z","timestamp":1751154867000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/373992-benralizumab-in-corticosteroid-refractory-drug-reaction-with-eosinophilia-and-systemic-symptoms-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.86932","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6,28]]}}}